| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sinusitis | 35 | 2023 | 187 | 12.480 |
Why?
|
| Rhinitis | 32 | 2023 | 165 | 12.010 |
Why?
|
| Paranasal Sinuses | 16 | 2022 | 63 | 4.860 |
Why?
|
| Paranasal Sinus Neoplasms | 12 | 2022 | 53 | 4.630 |
Why?
|
| Endoscopy | 26 | 2023 | 181 | 4.260 |
Why?
|
| Nose Neoplasms | 11 | 2022 | 34 | 4.060 |
Why?
|
| Nasal Polyps | 11 | 2023 | 62 | 4.010 |
Why?
|
| Chronic Disease | 32 | 2023 | 495 | 3.430 |
Why?
|
| Retrospective Studies | 55 | 2023 | 3273 | 2.770 |
Why?
|
| Head and Neck Neoplasms | 10 | 2023 | 133 | 2.580 |
Why?
|
| Humans | 118 | 2023 | 29361 | 2.310 |
Why?
|
| Eosinophils | 4 | 2022 | 47 | 2.270 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 5 | 2020 | 11 | 2.110 |
Why?
|
| Coronavirus Infections | 7 | 2020 | 86 | 2.090 |
Why?
|
| Pneumonia, Viral | 7 | 2020 | 89 | 2.080 |
Why?
|
| Betacoronavirus | 7 | 2020 | 75 | 2.070 |
Why?
|
| Neoplasm Staging | 14 | 2021 | 340 | 2.060 |
Why?
|
| Survival Rate | 18 | 2021 | 349 | 1.940 |
Why?
|
| SEER Program | 11 | 2019 | 38 | 1.900 |
Why?
|
| Middle Aged | 57 | 2023 | 9823 | 1.830 |
Why?
|
| Eosinophilia | 5 | 2019 | 47 | 1.780 |
Why?
|
| Female | 68 | 2021 | 16211 | 1.750 |
Why?
|
| Male | 64 | 2021 | 15637 | 1.680 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2021 | 24 | 1.670 |
Why?
|
| Clinical Laboratory Techniques | 3 | 2020 | 34 | 1.640 |
Why?
|
| Nasal Mucosa | 3 | 2019 | 16 | 1.500 |
Why?
|
| Nasal Cavity | 5 | 2020 | 35 | 1.450 |
Why?
|
| Prognosis | 15 | 2021 | 840 | 1.370 |
Why?
|
| Melanoma | 3 | 2021 | 52 | 1.320 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2022 | 178 | 1.300 |
Why?
|
| Adult | 38 | 2023 | 8604 | 1.290 |
Why?
|
| Laryngeal Neoplasms | 7 | 2023 | 30 | 1.240 |
Why?
|
| Frontal Sinus | 2 | 2017 | 12 | 1.190 |
Why?
|
| Sarcoma | 3 | 2021 | 65 | 1.120 |
Why?
|
| Aged | 40 | 2023 | 9447 | 1.110 |
Why?
|
| Treatment Outcome | 20 | 2023 | 3476 | 1.020 |
Why?
|
| Age Factors | 8 | 2020 | 845 | 0.980 |
Why?
|
| Adenocarcinoma | 3 | 2021 | 189 | 0.970 |
Why?
|
| United States | 16 | 2021 | 2332 | 0.950 |
Why?
|
| Nasal Surgical Procedures | 4 | 2019 | 8 | 0.950 |
Why?
|
| Otolaryngology | 5 | 2021 | 27 | 0.950 |
Why?
|
| Cerebrospinal Fluid Rhinorrhea | 1 | 2023 | 10 | 0.940 |
Why?
|
| Intracranial Hypertension | 1 | 2023 | 14 | 0.940 |
Why?
|
| Smell | 3 | 2020 | 18 | 0.930 |
Why?
|
| Simulation Training | 2 | 2020 | 34 | 0.910 |
Why?
|
| Nose | 8 | 2021 | 36 | 0.900 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 2 | 2020 | 2 | 0.890 |
Why?
|
| Skull Base | 5 | 2023 | 26 | 0.860 |
Why?
|
| Maxillary Sinus Neoplasms | 3 | 2020 | 6 | 0.850 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 137 | 0.810 |
Why?
|
| Pandemics | 8 | 2020 | 236 | 0.790 |
Why?
|
| Postoperative Complications | 6 | 2022 | 957 | 0.780 |
Why?
|
| Neutrophils | 2 | 2018 | 117 | 0.780 |
Why?
|
| Immunosuppressive Agents | 2 | 2019 | 132 | 0.780 |
Why?
|
| Ethmoid Sinus | 2 | 2017 | 11 | 0.760 |
Why?
|
| Nasopharynx | 1 | 2020 | 7 | 0.750 |
Why?
|
| Laryngopharyngeal Reflux | 1 | 2020 | 2 | 0.750 |
Why?
|
| Personnel, Hospital | 1 | 2020 | 17 | 0.750 |
Why?
|
| Neoplasm Grading | 6 | 2021 | 45 | 0.750 |
Why?
|
| Lacrimal Apparatus | 2 | 2017 | 2 | 0.740 |
Why?
|
| Optical Imaging | 2 | 2017 | 7 | 0.740 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2020 | 4 | 0.740 |
Why?
|
| Olfaction Disorders | 5 | 2021 | 53 | 0.730 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 24 | 0.730 |
Why?
|
| Reoperation | 3 | 2019 | 933 | 0.730 |
Why?
|
| Voice Quality | 1 | 2019 | 5 | 0.710 |
Why?
|
| Preoperative Care | 1 | 2020 | 135 | 0.700 |
Why?
|
| Quality of Life | 4 | 2020 | 664 | 0.700 |
Why?
|
| Maxillary Diseases | 1 | 2018 | 3 | 0.680 |
Why?
|
| Severity of Illness Index | 9 | 2021 | 1113 | 0.680 |
Why?
|
| Insurance Coverage | 1 | 2019 | 13 | 0.680 |
Why?
|
| Prednisone | 1 | 2018 | 67 | 0.660 |
Why?
|
| Registries | 2 | 2018 | 189 | 0.650 |
Why?
|
| Osteoblastoma | 1 | 2018 | 3 | 0.650 |
Why?
|
| Young Adult | 17 | 2020 | 1935 | 0.640 |
Why?
|
| Adolescent | 17 | 2020 | 2280 | 0.640 |
Why?
|
| Child | 13 | 2022 | 1345 | 0.630 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 100 | 0.630 |
Why?
|
| Neoplasms, Second Primary | 1 | 2018 | 30 | 0.630 |
Why?
|
| Olfactory Nerve | 1 | 2017 | 1 | 0.630 |
Why?
|
| Olfactory Receptor Neurons | 1 | 2017 | 1 | 0.630 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2022 | 770 | 0.630 |
Why?
|
| Therapeutic Irrigation | 1 | 2017 | 66 | 0.600 |
Why?
|
| Respiratory Tract Diseases | 1 | 2017 | 6 | 0.600 |
Why?
|
| Desensitization, Immunologic | 1 | 2017 | 5 | 0.600 |
Why?
|
| Stents | 1 | 2017 | 76 | 0.590 |
Why?
|
| Frontal Sinusitis | 1 | 2016 | 3 | 0.570 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 379 | 0.570 |
Why?
|
| Dissection | 1 | 2016 | 27 | 0.560 |
Why?
|
| Biofilms | 1 | 2016 | 15 | 0.560 |
Why?
|
| Aspirin | 1 | 2017 | 83 | 0.550 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 107 | 0.550 |
Why?
|
| Tongue Neoplasms | 3 | 2021 | 16 | 0.550 |
Why?
|
| Combined Modality Therapy | 4 | 2021 | 364 | 0.550 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 3 | 2021 | 28 | 0.550 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 90 | 0.550 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2023 | 184 | 0.540 |
Why?
|
| Nose Diseases | 1 | 2015 | 8 | 0.540 |
Why?
|
| Databases, Factual | 6 | 2021 | 330 | 0.500 |
Why?
|
| Inflammation | 4 | 2023 | 345 | 0.500 |
Why?
|
| Cochlear Implantation | 2 | 2010 | 22 | 0.470 |
Why?
|
| Risk Factors | 10 | 2021 | 2446 | 0.460 |
Why?
|
| Carcinoma | 3 | 2020 | 57 | 0.460 |
Why?
|
| Temporal Bone | 2 | 2010 | 10 | 0.460 |
Why?
|
| Tertiary Care Centers | 4 | 2020 | 66 | 0.450 |
Why?
|
| Prospective Studies | 7 | 2023 | 1812 | 0.430 |
Why?
|
| Encephalocele | 2 | 2023 | 26 | 0.430 |
Why?
|
| Neck Dissection | 3 | 2021 | 17 | 0.430 |
Why?
|
| Glossitis | 1 | 2011 | 1 | 0.420 |
Why?
|
| Mometasone Furoate | 2 | 2022 | 6 | 0.420 |
Why?
|
| Sutures | 1 | 2011 | 41 | 0.410 |
Why?
|
| Pituitary Neoplasms | 3 | 2020 | 20 | 0.400 |
Why?
|
| Abscess | 1 | 2011 | 26 | 0.400 |
Why?
|
| Lymphatic Metastasis | 3 | 2021 | 81 | 0.400 |
Why?
|
| Cochlear Implants | 2 | 2010 | 30 | 0.390 |
Why?
|
| Aged, 80 and over | 14 | 2021 | 4851 | 0.390 |
Why?
|
| Smoking | 3 | 2020 | 194 | 0.380 |
Why?
|
| Incidence | 7 | 2019 | 756 | 0.380 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2010 | 16 | 0.380 |
Why?
|
| Speech Perception | 2 | 2010 | 48 | 0.380 |
Why?
|
| Preoperative Period | 3 | 2019 | 65 | 0.370 |
Why?
|
| Rhinoplasty | 3 | 2023 | 11 | 0.360 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2010 | 32 | 0.360 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2010 | 46 | 0.360 |
Why?
|
| Cohort Studies | 7 | 2020 | 1939 | 0.360 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 1829 | 0.350 |
Why?
|
| Leukocyte Count | 2 | 2019 | 92 | 0.350 |
Why?
|
| Laryngectomy | 4 | 2023 | 17 | 0.350 |
Why?
|
| Rhinitis, Allergic | 2 | 2020 | 24 | 0.340 |
Why?
|
| Wound Healing | 2 | 2020 | 168 | 0.330 |
Why?
|
| Cerebrospinal Fluid Leak | 3 | 2023 | 18 | 0.330 |
Why?
|
| Diagnosis, Differential | 5 | 2020 | 389 | 0.330 |
Why?
|
| Telemedicine | 2 | 2020 | 99 | 0.330 |
Why?
|
| Disease Management | 2 | 2020 | 114 | 0.310 |
Why?
|
| Survival Analysis | 5 | 2021 | 298 | 0.310 |
Why?
|
| Salvage Therapy | 3 | 2023 | 36 | 0.310 |
Why?
|
| Recurrence | 3 | 2018 | 350 | 0.300 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2020 | 52 | 0.300 |
Why?
|
| Child, Preschool | 6 | 2016 | 641 | 0.300 |
Why?
|
| Internship and Residency | 2 | 2021 | 211 | 0.300 |
Why?
|
| Chicago | 2 | 2020 | 865 | 0.300 |
Why?
|
| Margins of Excision | 3 | 2021 | 17 | 0.280 |
Why?
|
| Cadaver | 2 | 2017 | 359 | 0.280 |
Why?
|
| Postoperative Period | 4 | 2022 | 288 | 0.270 |
Why?
|
| Chemoradiotherapy | 2 | 2023 | 67 | 0.250 |
Why?
|
| Nasal Septum | 2 | 2023 | 9 | 0.250 |
Why?
|
| Case-Control Studies | 2 | 2023 | 638 | 0.250 |
Why?
|
| Disease-Free Survival | 4 | 2019 | 175 | 0.230 |
Why?
|
| Surgical Flaps | 2 | 2021 | 49 | 0.230 |
Why?
|
| Reproducibility of Results | 3 | 2022 | 788 | 0.230 |
Why?
|
| Nasal Obstruction | 1 | 2023 | 5 | 0.230 |
Why?
|
| Taste Disorders | 2 | 2021 | 5 | 0.230 |
Why?
|
| Neurosurgical Procedures | 2 | 2022 | 150 | 0.220 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 6 | 0.220 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2022 | 23 | 0.210 |
Why?
|
| Papillomavirus Infections | 1 | 2022 | 37 | 0.210 |
Why?
|
| Neoplasm Invasiveness | 3 | 2021 | 68 | 0.210 |
Why?
|
| Nasal Lavage | 1 | 2021 | 2 | 0.210 |
Why?
|
| Pituitary-Adrenal System | 1 | 2021 | 11 | 0.210 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2021 | 14 | 0.210 |
Why?
|
| Skull Base Neoplasms | 1 | 2021 | 15 | 0.210 |
Why?
|
| Social Media | 1 | 2022 | 27 | 0.200 |
Why?
|
| Fibrosis | 2 | 2018 | 39 | 0.200 |
Why?
|
| Hydrocortisone | 1 | 2021 | 43 | 0.200 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2021 | 62 | 0.200 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2021 | 75 | 0.200 |
Why?
|
| Radiology | 1 | 2021 | 22 | 0.200 |
Why?
|
| Chondrosarcoma | 1 | 2021 | 31 | 0.200 |
Why?
|
| Gloves, Surgical | 1 | 2021 | 7 | 0.200 |
Why?
|
| Air Pollution | 1 | 2021 | 17 | 0.200 |
Why?
|
| Neoplasm Seeding | 1 | 2021 | 7 | 0.200 |
Why?
|
| Professional Role | 1 | 2021 | 27 | 0.200 |
Why?
|
| Air Pollutants | 1 | 2021 | 12 | 0.200 |
Why?
|
| Natural Killer T-Cells | 1 | 2020 | 5 | 0.190 |
Why?
|
| Surgical Instruments | 1 | 2021 | 25 | 0.190 |
Why?
|
| Empty Sella Syndrome | 1 | 2020 | 4 | 0.190 |
Why?
|
| Operating Rooms | 1 | 2020 | 14 | 0.190 |
Why?
|
| Glottis | 1 | 2020 | 3 | 0.190 |
Why?
|
| Observer Variation | 1 | 2021 | 118 | 0.190 |
Why?
|
| Anti-Bacterial Agents | 2 | 2016 | 402 | 0.190 |
Why?
|
| Hemostatic Techniques | 1 | 2020 | 8 | 0.190 |
Why?
|
| Eczema | 1 | 2020 | 4 | 0.190 |
Why?
|
| Surgery Department, Hospital | 1 | 2020 | 5 | 0.190 |
Why?
|
| Neuroendoscopy | 1 | 2020 | 8 | 0.190 |
Why?
|
| Epistaxis | 1 | 2020 | 9 | 0.190 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2020 | 7 | 0.190 |
Why?
|
| Pharynx | 1 | 2020 | 14 | 0.190 |
Why?
|
| Urban Health Services | 1 | 2020 | 13 | 0.190 |
Why?
|
| Inservice Training | 1 | 2020 | 26 | 0.190 |
Why?
|
| Microbiota | 2 | 2018 | 105 | 0.190 |
Why?
|
| Airway Management | 1 | 2020 | 16 | 0.190 |
Why?
|
| Tracheostomy | 1 | 2020 | 19 | 0.190 |
Why?
|
| Education, Nursing, Continuing | 1 | 2020 | 27 | 0.190 |
Why?
|
| Cryosurgery | 1 | 2020 | 20 | 0.190 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 21 | 0.180 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 79 | 0.180 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2018 | 79 | 0.180 |
Why?
|
| Ambulatory Care | 1 | 2020 | 75 | 0.180 |
Why?
|
| Papilloma, Inverted | 1 | 2020 | 14 | 0.180 |
Why?
|
| Sella Turcica | 1 | 2019 | 5 | 0.180 |
Why?
|
| Surgeons | 1 | 2021 | 76 | 0.180 |
Why?
|
| Trachea | 1 | 2020 | 31 | 0.180 |
Why?
|
| Surgical Wound | 1 | 2019 | 11 | 0.180 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 206 | 0.180 |
Why?
|
| Drug-Eluting Stents | 1 | 2019 | 11 | 0.180 |
Why?
|
| Steroids | 1 | 2019 | 22 | 0.180 |
Why?
|
| Postoperative Care | 1 | 2020 | 127 | 0.180 |
Why?
|
| Food Hypersensitivity | 1 | 2020 | 57 | 0.180 |
Why?
|
| Skin | 1 | 2020 | 117 | 0.170 |
Why?
|
| Elective Surgical Procedures | 1 | 2019 | 43 | 0.170 |
Why?
|
| Craniopharyngioma | 1 | 2018 | 3 | 0.170 |
Why?
|
| Sphenoid Bone | 1 | 2018 | 4 | 0.170 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 37 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 340 | 0.170 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2018 | 3 | 0.170 |
Why?
|
| Bacteroidetes | 1 | 2018 | 4 | 0.170 |
Why?
|
| Physicians | 1 | 2020 | 115 | 0.170 |
Why?
|
| Firmicutes | 1 | 2018 | 6 | 0.170 |
Why?
|
| Mass Screening | 1 | 2020 | 177 | 0.170 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 215 | 0.170 |
Why?
|
| Hemostasis, Surgical | 1 | 2018 | 15 | 0.160 |
Why?
|
| Fibroma, Ossifying | 1 | 2018 | 5 | 0.160 |
Why?
|
| Osteoma | 1 | 2018 | 5 | 0.160 |
Why?
|
| Vasoconstrictor Agents | 1 | 2018 | 28 | 0.160 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 148 | 0.160 |
Why?
|
| Self Report | 1 | 2019 | 218 | 0.160 |
Why?
|
| Asthma | 1 | 2020 | 138 | 0.160 |
Why?
|
| Time Factors | 2 | 2021 | 1618 | 0.160 |
Why?
|
| Illinois | 1 | 2019 | 241 | 0.160 |
Why?
|
| Epinephrine | 1 | 2018 | 35 | 0.160 |
Why?
|
| Diagnostic Errors | 1 | 2018 | 40 | 0.160 |
Why?
|
| Clinical Competence | 1 | 2020 | 230 | 0.160 |
Why?
|
| Age Distribution | 1 | 2018 | 94 | 0.160 |
Why?
|
| Sex Distribution | 1 | 2018 | 87 | 0.160 |
Why?
|
| Lymphoma | 1 | 2018 | 44 | 0.160 |
Why?
|
| Drugs, Investigational | 1 | 2017 | 8 | 0.160 |
Why?
|
| Radiation Injuries | 1 | 2017 | 34 | 0.150 |
Why?
|
| Invasive Fungal Infections | 1 | 2017 | 4 | 0.150 |
Why?
|
| Frozen Sections | 1 | 2017 | 11 | 0.150 |
Why?
|
| Aspergillosis | 1 | 2017 | 10 | 0.150 |
Why?
|
| Mucormycosis | 1 | 2017 | 8 | 0.150 |
Why?
|
| Parathyroid Glands | 1 | 2017 | 7 | 0.150 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 79 | 0.150 |
Why?
|
| Respiratory Function Tests | 1 | 2017 | 32 | 0.150 |
Why?
|
| Pseudomonas Infections | 1 | 2017 | 59 | 0.150 |
Why?
|
| Carcinoma, Small Cell | 1 | 2016 | 71 | 0.150 |
Why?
|
| Mucous Membrane | 1 | 2016 | 40 | 0.140 |
Why?
|
| Radiopharmaceuticals | 1 | 2016 | 48 | 0.140 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2016 | 39 | 0.140 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 340 | 0.140 |
Why?
|
| Neurilemmoma | 1 | 2015 | 13 | 0.130 |
Why?
|
| Infant | 3 | 2015 | 531 | 0.130 |
Why?
|
| Immunity, Innate | 1 | 2016 | 90 | 0.130 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2016 | 100 | 0.130 |
Why?
|
| Eye Neoplasms | 1 | 2014 | 5 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2021 | 162 | 0.130 |
Why?
|
| Tertiary Healthcare | 1 | 2014 | 2 | 0.120 |
Why?
|
| Lymphatic Vessels | 1 | 2014 | 6 | 0.120 |
Why?
|
| California | 1 | 2014 | 31 | 0.120 |
Why?
|
| Elastic Modulus | 1 | 2014 | 12 | 0.120 |
Why?
|
| Viscosity | 1 | 2014 | 10 | 0.120 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2014 | 8 | 0.120 |
Why?
|
| Transducers | 1 | 2014 | 10 | 0.120 |
Why?
|
| Lymphocytes | 1 | 2014 | 110 | 0.120 |
Why?
|
| Image Enhancement | 1 | 2014 | 57 | 0.120 |
Why?
|
| Sex Factors | 3 | 2020 | 496 | 0.110 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2011 | 5 | 0.100 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2011 | 7 | 0.100 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 324 | 0.100 |
Why?
|
| Lasers, Solid-State | 1 | 2011 | 2 | 0.100 |
Why?
|
| Laryngeal Diseases | 1 | 2011 | 3 | 0.100 |
Why?
|
| Laser Therapy | 1 | 2011 | 13 | 0.100 |
Why?
|
| Carcinoma in Situ | 1 | 2011 | 9 | 0.100 |
Why?
|
| Immunotherapy | 2 | 2021 | 62 | 0.100 |
Why?
|
| Tongue | 2 | 2021 | 8 | 0.100 |
Why?
|
| Language Development | 1 | 2010 | 7 | 0.100 |
Why?
|
| Otoacoustic Emissions, Spontaneous | 1 | 2010 | 1 | 0.100 |
Why?
|
| Hair Cells, Auditory | 1 | 2010 | 2 | 0.100 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 1 | 2010 | 4 | 0.100 |
Why?
|
| Actinomycosis | 1 | 2010 | 3 | 0.090 |
Why?
|
| Meningitis, Bacterial | 1 | 2010 | 8 | 0.090 |
Why?
|
| Encephalitis | 1 | 2010 | 17 | 0.090 |
Why?
|
| Speech Intelligibility | 1 | 2010 | 12 | 0.090 |
Why?
|
| Audiometry | 1 | 2010 | 4 | 0.090 |
Why?
|
| Deafness | 1 | 2010 | 16 | 0.090 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2022 | 21 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2010 | 321 | 0.090 |
Why?
|
| Socioeconomic Factors | 2 | 2021 | 329 | 0.090 |
Why?
|
| Comorbidity | 2 | 2020 | 497 | 0.080 |
Why?
|
| Logistic Models | 2 | 2021 | 407 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 553 | 0.060 |
Why?
|
| Hypertrophy | 1 | 2023 | 19 | 0.060 |
Why?
|
| Temperature | 1 | 2023 | 76 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 1184 | 0.060 |
Why?
|
| Papillomaviridae | 1 | 2022 | 29 | 0.050 |
Why?
|
| Video Recording | 1 | 2022 | 47 | 0.050 |
Why?
|
| Information Dissemination | 1 | 2022 | 23 | 0.050 |
Why?
|
| Cerebrospinal Fluid Otorrhea | 1 | 2021 | 5 | 0.050 |
Why?
|
| Petrous Bone | 1 | 2021 | 7 | 0.050 |
Why?
|
| Length of Stay | 1 | 2023 | 317 | 0.050 |
Why?
|
| Education, Medical, Graduate | 1 | 2022 | 79 | 0.050 |
Why?
|
| Tourette Syndrome | 1 | 2021 | 37 | 0.050 |
Why?
|
| Hospitals, Teaching | 1 | 2021 | 33 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2021 | 15 | 0.050 |
Why?
|
| Cytological Techniques | 1 | 2021 | 14 | 0.050 |
Why?
|
| Particulate Matter | 1 | 2021 | 22 | 0.050 |
Why?
|
| Optic Chiasm | 1 | 2020 | 3 | 0.050 |
Why?
|
| Optic Nerve | 1 | 2020 | 6 | 0.050 |
Why?
|
| Aerosols | 1 | 2020 | 21 | 0.050 |
Why?
|
| Biometry | 1 | 2020 | 8 | 0.050 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 21 | 0.050 |
Why?
|
| Induction Chemotherapy | 1 | 2020 | 14 | 0.050 |
Why?
|
| Genomics | 1 | 2020 | 43 | 0.050 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 42 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 91 | 0.050 |
Why?
|
| Perception | 1 | 2020 | 83 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2020 | 65 | 0.050 |
Why?
|
| Emergencies | 1 | 2020 | 39 | 0.050 |
Why?
|
| Global Health | 1 | 2020 | 55 | 0.050 |
Why?
|
| Adenoma | 1 | 2020 | 42 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2020 | 56 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2020 | 149 | 0.050 |
Why?
|
| Internet | 1 | 2020 | 91 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2021 | 394 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 132 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 101 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 218 | 0.040 |
Why?
|
| Air | 1 | 2018 | 6 | 0.040 |
Why?
|
| Olfactory Bulb | 1 | 2019 | 16 | 0.040 |
Why?
|
| Metaplasia | 1 | 2018 | 11 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2019 | 132 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 22 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2018 | 57 | 0.040 |
Why?
|
| Patient Selection | 1 | 2020 | 232 | 0.040 |
Why?
|
| Phenotype | 1 | 2019 | 357 | 0.040 |
Why?
|
| Prevalence | 1 | 2020 | 491 | 0.040 |
Why?
|
| Administration, Topical | 1 | 2018 | 17 | 0.040 |
Why?
|
| Biodiversity | 1 | 2018 | 37 | 0.040 |
Why?
|
| Cranial Nerve Diseases | 1 | 2017 | 2 | 0.040 |
Why?
|
| Necrosis | 1 | 2017 | 26 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2018 | 85 | 0.040 |
Why?
|
| Basement Membrane | 1 | 2017 | 12 | 0.040 |
Why?
|
| Drug Design | 1 | 2017 | 30 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 295 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2020 | 678 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2018 | 86 | 0.040 |
Why?
|
| Biopsy | 1 | 2018 | 234 | 0.040 |
Why?
|
| Mucor | 1 | 2017 | 4 | 0.040 |
Why?
|
| Aspergillus | 1 | 2017 | 7 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2017 | 39 | 0.040 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2017 | 4 | 0.040 |
Why?
|
| Edema | 1 | 2017 | 38 | 0.040 |
Why?
|
| Ethmoid Bone | 1 | 2016 | 2 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 45 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 965 | 0.040 |
Why?
|
| Acute Disease | 1 | 2017 | 226 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 788 | 0.030 |
Why?
|
| Animals | 2 | 2017 | 4577 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 333 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 1220 | 0.030 |
Why?
|
| Decision Making | 1 | 2017 | 220 | 0.030 |
Why?
|
| Biomarkers | 1 | 2017 | 692 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2014 | 106 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2015 | 604 | 0.030 |
Why?
|
| Equipment Design | 1 | 2014 | 185 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2015 | 427 | 0.030 |
Why?
|
| Facial Pain | 1 | 2011 | 5 | 0.030 |
Why?
|
| Long-Term Care | 1 | 2011 | 58 | 0.030 |
Why?
|
| Granuloma, Laryngeal | 1 | 2011 | 1 | 0.020 |
Why?
|
| Leukoplakia | 1 | 2011 | 1 | 0.020 |
Why?
|
| Stroboscopy | 1 | 2011 | 1 | 0.020 |
Why?
|
| Polyps | 1 | 2011 | 3 | 0.020 |
Why?
|
| Laryngeal Edema | 1 | 2011 | 2 | 0.020 |
Why?
|
| Cysts | 1 | 2011 | 16 | 0.020 |
Why?
|
| Laryngoscopy | 1 | 2011 | 21 | 0.020 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2010 | 1 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2011 | 75 | 0.020 |
Why?
|
| Speech Production Measurement | 1 | 2010 | 2 | 0.020 |
Why?
|
| Auditory Threshold | 1 | 2010 | 15 | 0.020 |
Why?
|
| Hearing Tests | 1 | 2010 | 9 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2010 | 19 | 0.020 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2011 | 74 | 0.020 |
Why?
|
| Models, Animal | 1 | 2010 | 126 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2010 | 126 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 250 | 0.020 |
Why?
|
| Facial Asymmetry | 1 | 2009 | 1 | 0.020 |
Why?
|
| Esthetics | 1 | 2009 | 9 | 0.020 |
Why?
|
| Linear Models | 1 | 2010 | 254 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 432 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2010 | 502 | 0.020 |
Why?
|
| Mice | 1 | 2010 | 1620 | 0.020 |
Why?
|